Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).

Masahito KotakaShigeyoshi IwamotoHironaga SatakeDaisuke SakaiToshihiro KudoMutsumi FukunagaKen KonishiYoshihito IdeTaro IkumotoAkihito TsujiYasushi SanoTakeshi KatoNaotoshi SugimotoTaroh SatohAkiyoshi KanazawaTakayasu KurataTakeharu YamanakaNaohiro Tomita

Published in: International journal of clinical oncology (2020)

Reintroduction of oxaliplatin was feasible and achieved high RR or DCR in patients after more than 6 months post oxaliplatin adjuvant chemotherapy.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
acute lymphoblastic leukemia
acute myeloid leukemia
prognostic factors
peritoneal dialysis
metastatic colorectal cancer
diffuse large b cell lymphoma
multiple myeloma